Journal article icon

Journal article

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens

Abstract:

The 2014-15 Ebola outbreak in West Africa highlighted the potential for large disease outbreaks caused by emerging pathogens and has generated considerable focus on preparedness for future epidemics. Here we discuss drivers, strategies and practical considerations for developing vaccines against outbreak pathogens. Chimpanzee adenoviral (ChAd) vectors have been developed as vaccine candidates for multiple infectious diseases and prostate cancer. ChAd vectors are safe and induce antigen-specif...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1080/21645515.2017.1383575

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
Expand authors...
Publisher:
Taylor and Francis Publisher's website
Journal:
Human Vaccines and Immunotherapeutics Journal website
Volume:
13
Issue:
12: The International Society for Vaccines 2016 Annual
Pages:
3020-3032
Publication date:
2017-10-30
Acceptance date:
2017-09-19
DOI:
EISSN:
2164-554X
ISSN:
2164-5515
Source identifiers:
729302
Pubs id:
pubs:729302
UUID:
uuid:1a9d62f3-5d24-4feb-bd87-973a2143baa5
Local pid:
pubs:729302
Deposit date:
2017-09-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP